Product Description
ATG-012, a KRAS inhibitor, and a potential combination agent with ATG-017 and ATG-101, is in late pre-clinical research stage, with IND submissions expected in 2022. (Sourced from: https://www.antengene.com/news/1496.html)
Mechanisms of Action: KRAS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Antengene Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|